Elevance Health, Inc. (NYSE:ELV) Receives $416.11 Average Price Target from Brokerages

Elevance Health, Inc. (NYSE:ELV) has been given a consensus rating of “Moderate Buy” by the twenty-three analysts that are covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $419.1579.

Several equities research analysts recently issued reports on ELV shares. Robert W. Baird raised their target price on shares of Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Barclays increased their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a report on Tuesday, May 26th. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. The Goldman Sachs Group lifted their price objective on Elevance Health from $350.00 to $370.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Bank of America increased their target price on Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a report on Thursday, June 4th.

Insider Buying and Selling at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.34% of the stock is owned by company insiders.

Institutional Trading of Elevance Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELV. Kemnay Advisory Services Inc. purchased a new position in shares of Elevance Health during the 4th quarter worth $31,000. J.Safra Asset Management Corp purchased a new stake in shares of Elevance Health in the 4th quarter worth $32,000. WealthCollab LLC increased its stake in shares of Elevance Health by 42.2% in the 1st quarter. WealthCollab LLC now owns 91 shares of the company’s stock worth $27,000 after purchasing an additional 27 shares in the last quarter. ORG Partners LLC raised its holdings in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after purchasing an additional 59 shares during the period. Finally, Dorato Capital Management purchased a new position in Elevance Health during the fourth quarter valued at $41,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Elevance Health Price Performance

Shares of NYSE:ELV opened at $416.97 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The firm has a market cap of $90.55 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 2.36 and a beta of 0.67. The business has a 50-day simple moving average of $389.48 and a two-hundred day simple moving average of $350.67. Elevance Health has a fifty-two week low of $273.71 and a fifty-two week high of $427.19.

Elevance Health (NYSE:ELV) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter last year, the firm posted $11.97 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts expect that Elevance Health will post 26.86 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.6%. Elevance Health’s dividend payout ratio is presently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.